PharmaCyte Biotech Inc (PMCB)

[JimboPMCB]

I was curious to see what organizations think about PMCB and this is ones response.

Thank you for contacting the Pancreatic Cancer Action Network. My name is Celeste and I am a Patient Central Associate. I would be happy to assist you.

We are aware of the research that is being conducted by PharmaCyte Biotech. I have provided some information below on the topic.

Please note that I am not a medical professional, nor does the Pancreatic Cancer Action Network have one on staff. Therefore, I am unable to provide any medical advice or treatment recommendations. The information below is intended to serve as an educational resource.

PharmaCyte Biotech acquired a technology that involves what they call encapsulated living cells, as a treatment for pancreatic cancer.

On their website they mention that there was a Phase II trial that was completed in pancreatic cancer patients. Below I have provided a link to the abstract for that trial.

Encapsulated Cells Expressing a Chemotherapeutic Activating Enzyme Allow the Targeting of Subtoxic Chemotherapy and Are Safe and Efficacious: Data from Two Clinical Trials in Pancreatic Cancer

I have also provided below a link to another article discussing this therapy.

Use of cell therapy as a means of targeting chemotherapy to inoperable pancreatic cancer.

Also on their website, PharmaCyte Biotech mentions that they will be conducting a pancreatic cancer clinical trial sometime soon, but they do not provide any specific information regarding the trial or when it will open to patient enrollment. We are not aware of any currently active trials here in the United States that are testing this technology.

I have included an article below that that discusses how the FDA Granted Orphan Drug Designation to PharmaCyte Biotech (previously Nuvilex) for pancreatic cancer treatment.

https://globenewswire.com/news-release/2014/12/22/693421/10113176/en/FDA-Grants-Orphan-Drug-Designation-to-Nuvilex-for-Pancreatic-Cancer-Treatment.html

This therapy is real as it is being investigated in the clinical trial setting. However, until this therapy completes the clinical trials process (Phase I, Phase II, and Phase III testing), we will not know whether or not this therapy is safe and effective in treating pancreatic cancer.

As you mentioned that you have a family history of cancer, I would like to mention that we have information on risk factors and genetic disorders associated with pancreatic cancer, along with information on research studies that high-risk individuals can join for potential early detection and to advance research. If you would like to receive this information, please let me know.

We also have a complimentary basic pancreatic cancer education packet. If you would like to receive it, please provide your mailing address.

I hope you find this information useful, James. If you have any further questions or need additional resources, please do not hesitate to contact me. I can be reached Monday – Friday, 7 a.m. to 3 p.m., Pacific Time toll-free at 877.272.6226, or by email at [e-mail].

Sincerely,
Celeste
______________________________________
Celeste O’Neill
Patient Central Associate
Pancreatic Cancer Action Network National Office
1500 Rosecrans Avenue, Suite 200
Manhattan Beach, CA 90266
Phone: [phone]
Toll-Free: 877.272.6226
Fax: [phone]
www.pancan.org

Information provided by the Pancreatic Cancer Action Network, Inc. (“PanCAN”) is not a substitute for medical advice, diagnosis, treatment or other health care services. PanCAN may provide information to you about physicians, products, services, clinical trials or treatments related to pancreatic cancer, but PanCAN does not recommend nor endorse any particular health care resource. In addition, please note that any personal information you provide to PanCAN's associates during telephone and/or email communications may be stored and used to help PanCAN achieve its mission of assisting patients with, and finding cures and treatments for, pancreatic cancer. Stored constituent information may be used to inform PanCAN programs and activities. Information also may be provided in aggregate or limited formats to third parties to guide future pancreatic cancer research and treatment efforts. PanCAN will not provide personal directly identifying information (such as your name or contact information) to such third parties without your prior written consent unless required or permitted by law to do so.

ADVANCE RESEARCH | SUPPORT PATIENTS | CREATE HOPE